满￥6666，赠豪华版黑神话悟空
Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
囊泡
/
细胞周期
帕金森与阿尔茨海默症
/ CDK / (R)-Roscovitine

(R)-Roscovitine 99%+

货号：A300507 同义名： CYC202;Seliciclib Ambeed 开学季，买赠积分，赢豪礼

(R)-Roscovitine（Seliciclib）是一种口服生物利用度高且选择性的CDK抑制剂，对CDK5、Cdc2和CDK2的IC50值分别为0.2 μM、0.65 μM和0.7 μM。

(R)-Roscovitine 化学结构 CAS号：186692-46-6
(R)-Roscovitine 化学结构
CAS号：186692-46-6
(R)-Roscovitine 3D分子结构
CAS号：186692-46-6
(R)-Roscovitine 化学结构 CAS号：186692-46-6
(R)-Roscovitine 3D分子结构 CAS号：186692-46-6
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

(R)-Roscovitine 纯度/质量文件 产品仅供科研

货号：A300507 标准纯度： 99%+
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Cell,2024. Ambeed. [ A125712 ]
• Cancer Discov., 2024. Ambeed. [ A285925 ]
• JMC, 2024, 67(17): 14974-14985. Ambeed. [ A288696 ]
• JMC, 2024, 67(17): 15061-15079. Ambeed. [ A524399 , A633512 , A144280 , A174613 ]
• EJNMMI Radiopharm. Chem., 2024, 9, 61. Ambeed. [ A1257961 , A622068 ]
更多 >
产品名称 Cdc ↓ CDK1 ↓ CDK19 ↓ CDK2 ↓ CDK3 ↓ CDK4 ↓ CDK5 ↓ CDK6 ↓ CDK7 ↓ CDK8 ↓ CDK9 ↓ CLK ↓ 其他靶点 纯度
XL413 hydrochloride ++++

Cdc7, IC50: 3.4 nM

 		99%+
SU9516 +++

CDK1, IC50: 40 nM

 		+++

CDK2, IC50: 22 nM

 		++

CDK4, IC50: 200 nM

 		99%+
RO-3306 +++

CDK1, Ki: 20 nM

 		SGK,ERK 98%
R547 ++++

CDK1/CyclinB, Ki: 2 nM

 		++++

CDK2/CyclinE, Ki: 3 nM

 		++++

CDK4/CyclinD1, Ki: 1 nM

 		99%+
BMS-265246 ++++

CDK1/CyclinB, IC50: 6 nM

 		++++

CDK2/CyclinE, IC50: 9 nM

 		+

CDK4/CyclinD, IC50: 230 nM

 		99%+
NU6027 +

CDK1, Ki: 2.5 μM

 		+

CDK2, Ki: 1.3 μM

 		DNA-PK 98%
Purvalanol A ++++

Cdc2/CyclinB, IC50: 4 nM

 		+++

CDK2/CyclinE, IC50: 35 nM

CDK2/CyclinA, IC50: 70 nM

 		+

CDK4/CyclinD1, IC50: 850 nM

 		99%+
SCH900776 ++

CDK2, IC50: 0.16 μM

 		99%+
AUZ 454 ++++

CDK2(A144C), Kd: 9.7 nM

CDK2(C118L), Kd: 18.6 nM

 		99%+
A-674563 HCl ++

CDK2, Ki: 46 nM

 		PKA 98%
JNJ-7706621 ++++

CDK1/CyclinB, IC50: 9 nM

 		++++

CDK2/CyclinE, IC50: 3 nM

CDK2/CyclinA, IC50: 4 nM

 		++

CDK3/CyclinE, IC50: 58 nM

 		+

CDK4/CyclinD1, IC50: 253 nM

 		++

CDK6/CyclinD1, IC50: 175 nM

 		99%+
AT7519 ++

CDK1/CyclinB, IC50: 210 nM

 		++

CDK2/CyclinA, IC50: 47 nM

 		+

CDK3/CyclinE, IC50: 360 nM

 		++

CDK4/CyclinD1, IC50: 100 nM

 		+++

CDK5/p35, IC50: 13 nM

 		++

CDK6/CyclinD3, IC50: 170 nM

 		++++

CDK9/CyclinT, IC50: <10 nM

 		98+%
PHA-793887 ++

CDK1/CyclinB, IC50: 60 nM

 		++++

CDK2/CyclinE, IC50: 8 nM

CDK2/CyclinA, IC50: 8 nM

 		++

CDK4/CyclinD1, IC50: 62 nM

 		++++

CDK5/p25, IC50: 5 nM

 		++++

CDK7/CyclinH, IC50: 10 nM

 		++

CDK9/CyclinT1, IC50: 138 nM

 		99%+
Milciclib +

CDK1/CyclinB, IC50: 398 nM

 		++

CDK2/CyclinE, IC50: 363 nM

CDK2/CyclinA, IC50: 45 nM

 		++

CDK4/CyclinD1, IC50: 160 nM

 		+

CDK5/p35, IC50: 265 nM

 		++

CDK7/CyclinH, IC50: 150 nM

 		99%+
Kenpaullone +

CDK1/CyclinB, IC50: 0.4μM

 		+

CDK2/CyclinE, IC50: 7.5μM

CDK2/CyclinA, IC50: 0.68μM

 		+

CDK5/p35, IC50: 0.85μM

 		98%
SNS-032 +++

CDK2/CyclinE, IC50: 48 nM

CDK2/CyclinA, IC50: 38 nM

 		+

CDK5/p35, IC50: 340 nM

 		++

CDK7/CyclinH, IC50: 62 nM

 		++++

CDK9/CyclinT, IC50: 4 nM

 		99%+
Dinaciclib ++++

CDK1, IC50: 3 nM

 		++++

CDK2, IC50: 1 nM

 		++++

CDK5, IC50: 1 nM

 		++++

CDK9, IC50: 4 nM

 		99%+
PHA-767491 hydrochloride ++++

Cdc7, IC50: 10 nM

 		+

CDK1, IC50: 250 nM

 		+

CDK2, IC50: 240 nM

 		+

CDK5, IC50: 460 nM

 		+++

CDK9, IC50: 34 nM

 		MK2 98%
(R)-Roscovitine +

Cdc2/CyclinB, IC50: 0.65 μM

 		+

CDK2/CyclinE, IC50: 0.7 μM

CDK2/CyclinA, IC50: 0.7 μM

 		++

CDK5/p35, IC50: 0.16 μM

 		99%+
Narazaciclib ++++

CDK4/CyclinD1, IC50: 3.87 nM

 		++++

CDK6/CyclinD1, IC50: 9.82 nM

 		RET 99%+
Palbociclib ++++

CDK4/CyclinD3, IC50: 9 nM

CDK4/CyclinD1, IC50: 11 nM

 		+++

CDK6/CyclinD2, IC50: 15 nM

 		99%
Abemaciclib ++++

CDK4, IC50: 2 nM

 		++++

CDK6, IC50: 10 nM

 		99%
Ribociclib ++++

CDK4, IC50: 10 nM

 		+++

CDK6, IC50: 39 nM

 		98%
Palbociclib isethionate ++++

CDK4/CyclinD3, IC50: 9 nM

CDK4/CyclinD1, IC50: 11 nM

 		+++

CDK6/CyclinD2, IC50: 15 nM

 		99%+
BS-181 HCl +++

CDK7, IC50: 21 nM

 		99%+
(E/Z)-THZ1 dihydrochloride ++++

CDK7, IC50: 3.2 nM

 		99%+
LDC4297 ++++

CDK7, IC50: 0.13 nM

 		99%+
Senexin A +

CDK19, Kd: 0.31 μM

 		+

CDK8, Kd: 0.83 μM

 		98+%
MSC2530818 ++++

CDK8, IC50: 2.6 nM

 		99%+
Wogonin ✔ 99%+
Riviciclib HCl ++

CDK1/CyclinB, IC50: 79 nM

 		+

CDK2/CyclinE, IC50: 2.54 μM

CDK2/CyclinA, IC50: 224 nM

 		++

CDK4/CyclinD1, IC50: 63 nM

 		+

CDK6/CyclinD3, IC50: 396 nM

 		+

CDK7/CyclinH, IC50: 2.87 μM

 		+++

CDK9/CyclinT1, IC50: 20 nM

 		99+%
LDC000067 +

CDK2, IC50: 2.441 μM

 		++

CDK9, IC50: 44 nM

 		98%
Flavopiridol +++

CDK1, IC50: 40 nM

 		+++

CDK2, IC50: 40 nM

 		+++

CDK4, IC50: 40 nM

 		+++

CDK6, IC50: 40 nM

 		+

CDK7, IC50: 300 nM

 		+++

CDK9, IC50: 20 nM

 		99%+
LY2857785 +

CDK7, IC50: 0.246 μM

 		+++

CDK8, IC50: 0.016 μM

 		+++

CDK9, IC50: 0.011 μM

 		99%+
AZD-5438 +++

CDK1, IC50: 16 nM

 		++++

CDK2, IC50: 6 nM

 		+++

CDK9, IC50: 20 nM

 		99%+
ML167 ++

Dyrk1B , IC50: 1648 nM

CLK4, IC50: 136 nM

 		99%+
(E/Z)-TG003 +++

mCLK4, IC50: 15 nM

mCLK1, IC50: 200 nM

 		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

(R)-Roscovitine 生物活性

靶点

  • CDK5

    CDK5/p35, IC50:0.16 μM

  • CDK2

    CDK2/CyclinE, IC50:0.7 μM

    CDK2/CyclinA, IC50:0.7 μM

  • Cdc

    Cdc2/CyclinB, IC50:0.65 μM
描述 The CDKs (cyclin dependent kinases), as direct regulators of specific phases of the cell cycle, can control cellular proliferation and transcription with their activating cyclin partners and subunit inhibitors. Roscovitine (Seliciclib, CYC202) is a CDK2 and CDK5 inhibitor with IC50 values of 0.65, 0.7, 0.7 and 0.16 μM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E and cdk5/p35 (measured by purified kinases activity), respectively. Roscovitine had a very limited effect on the cdk4/cyclin D1 and cdk6/cyclin D2 kinases (IC50 values >100 μM)[1]. It also exhibited the potency to CDK7/cyclin H with IC50 value of 0.49 μM. Roscovitine showed anti-growth effect against a panel of human tumor cell lines in cell culture, including A549, CHAGO-K1, NCI-H69, NCI-H460, LOVO, HCT15, HCT116, HT29, A498, ACHN, HT1376, MCF7, MDAMB435S, AN3CA, MES-SA, MES-SA/Dx5 and HepG2 cell lines, with IC50 values ranging from 7.9 - 30.2 μM for 72h[2]. Treatment of 60 μM roscovitine for 48h could inhibit the growth of L1210 cells and arrest cells in G2M[1]. Lovo xenografted mice treated with roscovitine, 100 mg/kg intraperitoneally 3 times daily at 8 hourly intervals for 5 days, exhibited a statistically significant reduction of 44.8% in tumor growth[2]. Phase 2 studies of roscovitine treatment for cystic fibrosis and Cushing’s Disease, and phase 1 study of roscovitine combined with sapacitabine treatment for advanced solid tumors are recruiting now (see https://www.clinicaltrials.gov/).
作用机制 Roscovitine behaves as a competitive inhibitor for ATP binding to cdc2.

(R)-Roscovitine 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
697 Growth Inhibition Assay IC50=12.6007 μM SANGER
A101D Growth Inhibition Assay IC50=18.3208 μM SANGER
A3-KAW Growth Inhibition Assay IC50=5.76116 μM SANGER
ACN Growth Inhibition Assay IC50=21.3389 μM SANGER

(R)-Roscovitine 动物研究

Dose Mice[4] (i.p.): min = 50 mg/kg, max = 350 mg/kg
Administration i.p.
Pharmacokinetics
Animal Rats[5]
Dose 25 mg/kg
Administration i.p.
Cmax 15.8 ± 0.4 μg/ml
Vss 102 ± 13 ml
CL 11.3 ± 1.2 ml/h
Tβ 7.2 ± 1.4 h (elimination half-life)
AUC 66.8 ± 7.2 h·μg/g
Tα 0.59 ± 0.14 h (absorption half-life)

(R)-Roscovitine 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00372073 Non-small Cell Lung Cancer Phase 2 Terminated March 2012 United States, Arizona ... 展开 >> Arizona Cancer Center Tucson, Arizona, United States, 85724 United States, California Pacific Coast Hematology Oncology Group Fountain Valley, California, United States, 92708 United States, Florida Pasco Hernando Oncology New Port Richey, Florida, United States, 34652 United States, Illinois Rush University Medical Center Chicago, Illinois, United States, 60612 The University of Chicago Chicago, Illinois, United States, 60637 United States, Maryland University of Maryland, Greenebaun Cancer Center Baltimore, Maryland, United States, 21201 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Nebraska Nebraska Medical Center Omaha, Nebraska, United States, 68198 United States, Nevada Nevada Cancer Research Foundation Las Vegas, Nevada, United States, 89106 VA Sierra Nevada Health Care System Reno, Nevada, United States, 89502 United States, New Mexico New Mexico Oncology Hematology Consultants Albuquerque, New Mexico, United States, 87109 United States, New York Columbia Presbyterian Medical Center New York, New York, United States, 10032 United States, Pennsylvania Penn State Milton S. Hershey Medical Center Hershey, Pennsylvania, United States, 17033 University of Pittsburg Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 United States, Tennessee The Family Cancer Center Collierville, Tennessee, United States, 38017 Vanderbilt University Medical Center Nashville, Tennessee, United States, 37232 United States, Texas Southwest Regional Cancer Center Austin, Texas, United States, 78705 Center for Oncology Research and Treatment Dallas, Texas, United States, 75230 East Texas Medical Center Tyler, Texas, United States, 75701 United States, Virginia Danville Hematology Oncology Danville, Virginia, United States, 24541 收起 <<
NCT00999401 Advanced Solid Tumors Phase 1 Unknown July 2018 United States, Massachusetts ... 展开 >> Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02115 Contact: Geoffrey Shapiro, M.D.    617-632-4942       Contact: Tracy Bell, R.N.    617.632.3482       Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Sara Tolaney, M.D.    617-632-2335       Contact: Leilani Anderson, RN    617-632-3129 收起 <<
NCT01333423 Breast Cancer Phase 1 Withdrawn - -

(R)-Roscovitine 参考文献

[1]Meijer L, Borgne A, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem. 1997 Jan 15;243(1-2):527-36.

[2]McClue SJ, Blake D, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer. 2002 Dec 10;102(5):463-8.

[3]De Azevedo WF, Leclerc S, et al. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem. 1997 Jan 15;243(1-2):518-26.

[4]Song H, Vita M, et al. Effect of the Cdk-inhibitor roscovitine on mouse hematopoietic progenitors in vivo and in vitro. Cancer Chemother Pharmacol. 2007 Nov;60(6):841-9. Epub 2007 Feb 22.

[5]Sallam H, Jimenez P, et al. Age-dependent pharmacokinetics and effect of roscovitine on Cdk5 and Erk1/2 in the rat brain. Pharmacol Res. 2008 Jul;58(1):32-7.

(R)-Roscovitine 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.82mL

0.56mL

0.28mL

14.11mL

2.82mL

1.41mL

28.21mL

5.64mL

2.82mL

(R)-Roscovitine 技术信息

CAS号186692-46-6
分子式C19H26N6O
分子量 354.449
别名 CYC202;Seliciclib;Roscovitin;R-roscovitine;Roscovitine
运输蓝冰
存储条件

粉末 Keep in dark place,Sealed in dry,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月
溶解度

DMSO: 105 mg/mL(296.23 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方

IP 5% DMSO+2% Tween80+40% PEG300+water 10 mg/mL clear

PO 0.5% CMC-Na 60 mg/mL suspension

Tags: (R)-Roscovitine | CYC202;Seliciclib;Roscovitin;R-roscovitine;Roscovitine | CDK | AmBeed-信号通路专用抑制剂 | (R)-Roscovitine 纯度/质量文件 | (R)-Roscovitine 亚型比较 | (R)-Roscovitine 生物活性 | (R)-Roscovitine 细胞研究 | (R)-Roscovitine 动物研究 | (R)-Roscovitine 临床数据 | (R)-Roscovitine 参考文献 | (R)-Roscovitine 实验方案 | (R)-Roscovitine 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z